Friday | October 7th 2022

CEO MESSAGE

Each week we look forward to sharing updates taking place within our ecosystem. A recent story published by Business in Vancouver highlights the impressive growth of local biotech companies looking for the infrastructure and space to expand. This conversation is incredibly important as we look ahead to the ongoing growth and innovations within our sector, and our ability to attract world-class talent - both now and in the future. Most importantly, it points to the accelerated growth of BC life sciences over the last few years, and the important role we play as the fastest growing life sciences sector in Canada.

 

On this note, we are so pleased to see that the Government of Canada has announced funding of $11.1 million for advancements to mRNA technology at UBC, and to boost the impact of BC biotechnology on the world stage. For more on the incredible life sciences leadership and innovation taking place within our province and beyond, we encourage you to check out this year’s Life Sciences magazine, recently published by Business in Vancouver.

 

Also, this week the Patented Medicine Prices Review Board released its new draft Guidelines and launched a consultation initiative to connect with stakeholders and interested members of the public. This will give effect to Health Canada’s July 2022 amendments to the Patented Medicines Regulations.

 

Genome Canada and the Canadian Institutes of Health Research (CIHR) recently released a joint report with 11 recommendations to strengthen Canada’s health data and research outcomes, and drive greater benefits for those that live in Canada. The key recommendations can be found here.


Member News

 

The Amyloidosis Research Consortium announced the launch of ASPIRE this week, a new initiative that brings life sciences companies together to drive collective impact in awareness, diagnosis, care, and health equity for patients with amyloidosis. Kudos to the LSBC member companies taking part in this initiative.

 

BioTalent Canada has opened applications for their inaugural I.D.E.A.L. Bioscience Employer Recognition Program to recognize organizations in the Canadian bio-economy that are leading the way in embodying the inclusion, diversity, equity and accessibility leader (IDEAL) principles and best practices needed to promote growth and success in the sector. Organizations that qualify can apply online (by November 7th!) to be considered for the recognition program here.

 

Events

 

There are also a number of upcoming events we want to highlight for the coming weeks. We will be hosting our next Showcase Series: Prince George event on October 12th. With a diverse roster of speakers from the political, academic and business arenas, this is a unique opportunity to learn more about our sector in the Prince George area. Register online to secure your spot for this free event today! Thrive Health is hosting a webinar on October 14th on the impact of new technologies on cancer survivorship care across Canada, featuring notable speakers including Dr. Anna Wilkinson, Associate Professor, Department of Family Medicine at the University of Ottawa and Dr. Mark Nazemi, who leads Thrive Health’s Clinical Solutions and Innovation department.

 

We are also excited to announce a new program in partnership with Biotech Primer, BioBasics 101: The Biology of Biotech for the Non-Scientist. This will be an intensive two-day master course on December 6-7. The course is designed to help non-scientists gain a foundational understanding of the science that forms the backbone of biopharma so you can converse more effectively with colleagues, clients, regulators, and scientists. Look for the invite to register next week!

 

Kudos


We are excited to announce the 10 companies and corresponding entrepreneurs-in-residence participating in our 2023 Investor Readiness Program (IRP), which kicks off this month! This intensive six-month program will help support 10 early-stage SMEs to become investor ready, with the help of our seasoned mentors. We look forward to following our SMEs on this exciting investor journey, and to sharing more in the months to come! Congratulations also to the 22 participants, representing a wide range of life sciences enterprises from across the country, who were selected to join Cohort V of the adMare Academy Executive Institute.

 

Congratulations to the LSBC member companies who were included in the Globe and Mail’s fourth annual list of Canada’s Top Growing Companies! Kudos again to the winners of BIOTECanada’s Gold Leaf Awards, announced last week - these awards celebrate the Canadian biotech industry, and further demonstrate the impressive companies that continue to drive innovation globally.

 

A well-deserved shout out to Dr. Pieter Cullis, who continues to be recognized (most recently last week at Bloom Burton 2022) for his significant contributions and innovations on the world stage. Dr. Cullis, co-founder of Acuitas Therapeutics and one of our LSBC board members, embodies everything we are so proud of and passionate about as a sector. He has led the development of lipid nanoparticle (LNP) delivery systems for molecular therapeutics, and his leadership has altered the course of the pandemic for people around the world!

 

People on the Move

 

Aspect Biosystems has recently welcomed three new board members to its Board of Directors: Dr. Nancy Krieger, CMO of Talaris Therapeutics; Dr. Don Haut, CEO of Carmine Therapeutics, and Dr. Devyn Smith, CEO of Arbor Biotechnologies. Congratulations to Dr. David Poon who joins Gandeeva Therapeutics as their Chief Business Officer and Dr. Matt Lucas as Chief Scientific Officer. Both bring invaluable pharmaceutical and biotech leadership to their new roles! And, congratulations also to Sebastian Steiner who joins VoxCell BioInnovation as their Head of Engineering this month as well.

 

From the LSBC family to yours, we wish you a wonderful Thanksgiving long weekend.

 

Until next week,

 

Wendy and the LSBC team


PLATINUM SPONSORS
 
 
 
 

Thrive Grand Rounds Speaker Series

Join us for a conversation between Dr. Anna Wilkinson Associate Professor at the University of Ottawa, Department of Family Medicine and Thrive Health’s Manager of Clinical Solutions & Innovation, Dr. Mark Nazemi to discuss the future of cancer survivorship care across Canada, and how new technologies are broadening the scope of survivor support...READ MORE

 

AbCellera Announces Presentation of Data from CD3 T-Cell Engager Platform at SITC 2022 

AbCellera announced a presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, to be held virtually and at the Boston Convention & Exhibition Center from November 8 to 12, 2022...READ MORE

 

adMare BioInnovations Announces a Strong Cohort for Its Academy’s Executive Institute 2022-2023 Program

adMare BioInnovations is pleased to announce that 22 participants representing a wide range of life sciences enterprises from across the country were selected to join Cohort V of the adMare Academy Executive Institute...READ MORE

 

SFU Researcher Receives Michael Smith Health Research Award for Work Harnessing Machine Learning to Advance Genetic Sequencing

SFU Statistics and Actuarial Science researcher Lloyd Elliott has received a Michael Smith Health Research BC Scholar Award to support his work using machine learning to understand how genetics affect brain function and neurodegenerative diseases...READ MORE

 

UBC Faculty of Medicine Researchers Receive Federal Support to Advance mRNA Vaccine Technologies

The Honourable Harjit S. Sajjan, Minister for International Development and Minister responsible for the Pacific Economic Development Agency of Canada (PacifiCan), announced the funding through PacifiCan for the projects to enhance the delivery and efficacy of mRNA vaccines...READ MORE

 

BioTalent Canada Calls for Applications for new I.D.E.A.L. Bioscience Employer Recognition Program

BioTalent Canada announced that its recently launched I.D.E.A.L. Bioscience EmployerTM recognition program is now accepting applications. This new employer recognition program, which represents Inclusivity, Diversity, Equity, and Accessibility Leadership, will recognize organizations in Canada’s bio-economy embodying the diverse and inclusive corporate principles needed to promote growth and success in the sector...READ MORE

 

Pfizer Announces Positive Topline Results from Phase 3 TALAPRO-2 Trial

Pfizer Inc. announced positive topline results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide) compared to placebo plus XTANDI in men with metastatic castration-resistant prostate cancer (mCRPC), with or without homologous recombination repair (HRR) gene mutations...READ MORE

 

Roche Receives FDA Approval for First Companion Diagnostic to Identify Patients with HER2 Low Metastatic Breast Cancer Eligible for ENHERTU

Roche announced that the US Food and Drug Administration approved the PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody* to identify metastatic breast cancer patients with low HER2 expression for whom ENHERTU® (fam-trastuzumab deruxtecan-nxki) may be considered as a targeted treatment. ENHERTU is a specifically engineered HER2-directed antibody drug conjugate being jointly developed and commercialised by AstraZeneca and Daiichi Sankyo...READ MORE

 

Pieter Cullis Receives the 2022 Bloom Burton Award

Pieter Cullis led the development of lipid nanoparticle (LNP) delivery systems for molecular therapeutics at Acuitas Therapeutics. The result of a lifetime of dedicated research driven by scientific curiosity, LNP delivery systems are a critical technology that help to accelerate, among other life-saving therapies, mRNA vaccine development...READ MORE

 

Eupraxia Pharmaceuticals Announces Expansion of Intellectual Property For EP-104IAR

Eupraxia Pharmaceuticals Inc., a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, announced the grant of a patent and a notice of allowance for EP-104IAR, the companies lead product...READ MORE

INDUSTRY NEWS
 

Appointments to the National Research Council of Canada

The Federal government is committed to improving the lives of Canadians through ongoing collaboration with industry and academia in the areas of research and development; delivering innovative ideas and bringing new technologies to market...READ MORE

 

PMPRB Notice and Comment – Consultation on new Draft Guidelines

The Patented Medicine Prices Review Board released its new draft Guidelines and launched a 60-day consultation period with stakeholders and interested members of the public. This consultation gives effect to Health Canada’s July 2022 amendments to the Patented Medicines Regulations, which strengthen and modernize Canada’s pricing framework for patented drugs, and further the Board’s longstanding commitment to modernize and simplify its administrative framework...READ MORE

 

New Initiative Brings Leading Life Sciences Companies Together to Drive Collective Impact in Awareness, Diagnosis, Care, and Health Equity for Patients with Amyloidosis

The Amyloidosis Research Consortium, a patient-led research organization for amyloidosis diseases, announces the launch of ASPIRE: Amyloidosis Stakeholder Partnerships for Impact Reach and Equity, a collaborative of biotech and pharmaceutical companies committed to advancing solutions, improving diagnosis and systems of care, and addressing obstacles to health equity on behalf of amyloidosis patients...READ MORE

B.C. Biotech Real Estate Awakening from ‘Nuclear Winter’

Competition for the limited inventory of real estate suitable for biotech is intensifying. Purpose-built labs in Vancouver’s life sciences sector were in a state of a “nuclear winter” just prior to medicinal and recreational cannabis getting green lights in the previous decade, according to Blair Quinn....READ MORE

LSBC IN THE NEWS

 
 

Life Sciences BC Announces Companies and Mentors of Third Annual Investor Readiness Program

Life Sciences BC announced the companies and mentors participating in its 2023 Investor Readiness Program. Through an intensive six-month program, 10 early-stage small and mid-size enterprises (SMEs) in British Columbia’s life sciences sector are paired with 10 entrepreneurs-in-residence to support the SMEs to become investor-ready...READ MORE

GOLD SPONSORS
 
 
 
 
 
 

Manager, IT



Abdera Therapeutics Inc. is a precision oncology company developing next-generation targeted radiation therapies- one of the most cutting-edge and highly promising areas of drug development. The company is built on a proprietary modular technology platform optimized for the delivery of radioisotopes to selectively destroy tumor cells while sparing healthy cells. Abdera is using this platform to enable the rapid development of a broad range of safe and efficacious therapies serving cancer patients with limited treatment options.


Abdera Therapeutics is growing rapidly and seeking key new team members who thrive at the cutting-edge of innovation. Come join us and be a part of the ground-breaking team set to unlock the power of targeted radiotherapy!




LEARN MORE

Project Manager



AbCellera is looking for an experienced Project Manager to lead a portfolio of projects that span their tech stack, from discovery to pre-clinical and clinical development. The successful candidate will work with their scientists, partners and collaborators to push the frontiers of science as they expand their tech stack and solve challenging problems in biology.


The ideal candidate is someone with demonstrated experience in managing complex, large-scale research portfolios, partnering with scientific experts to lead cross-functional teams; who is able to find harmony between waterfall, agile and hybrid work styles; who enjoys finding creative solutions to unexpected challenges and competing priorities; and who takes pride in the accomplishments of the team.




LEARN MORE

Senior Scientist



Alpha-9 is seeking a Senior Scientist to drive discovery efforts for new targeted radiopharmaceutical products. This person will be responsible for one or more discovery programs, including design and oversight of preclinical experiments leading to viable diagnostic and therapeutic clinical candidates. The ideal candidate will have experience with radiopharmaceutical development.


We are an early-stage company, so this is a highly visible and impactful role in our growing organization. The ideal candidate will be a self-starter with the desire to collaborate cross-functionally and strive in a fast-paced environment. 






LEARN MORE

 
SILVER SPONSORS
 
 
 
 
 
 
 
 
 
 
 
New Member Welcome

Translational research at the Life Sciences Institute is making global impacts on human health and the wellbeing of our planet. Their innovative, interdisciplinary science is changing the way health care is practiced, and finding more sustainable ways to harvest energy from our surroundings that minimize environmental costs.
















Visit Website

Member Spotlight

Deloitte provides audit & assurance, consulting, financial advisory, risk advisory, tax and related services to public and private clients spanning multiple industries. Deloitte serves four out of five Fortune Global 500® companies through a globally connected network of member firms in more than 150 countries and territories bringing world-class capabilities, insights and service to address clients’ most complex business challenges. To learn more about how Deloitte’s approximately 264,000 professionals—9,400 of whom are based in Canada—make an impact that matters, please connect with us on LinkedIn, Twitter or Facebook.









Visit Website

 
 
 
BRONZE SPONSORS
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Post a Job on the LSBC Website!

LSBC Membership Discounts on Job Postings

 

As an LSBC member, your first five job postings EARN a free repost on BioTalent Canada's The Petri Dish. After your first five posts, you will also receive 25% off all job postings on The Petri Dish. Want more info? Contact talent@lifesciencesbc.ca.

Facebook  Twitter  Linkedin  Instagram